Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Pediatric Oncology
Gefitinib demonstrates efficacy in children with refractory solid tumors
October 25th, 2005
Scientists observe that gefitinib demonstrates efficacy in children with refractory solid tumors. "Epidermal growth factor receptor is expressed in pediatric malignant solid tumors. We conducted a phase I trial of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in children with refractory solid tumors. Gefitinib (150, 300, 400, or 500 mg/m2) was administered orally to cohorts of 3 to 6 patients once daily continuously until disease progression or significant toxicity," researchers in the United States reported. "Pharmacokinetic studies were performed during course one (day 1 through 28). Of the 25 enrolled...
Source: Cancer Weekly (2005-10-25)
|
